drugset
drugset / Trial / NCT04019262

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

NCT04019262 ↗

Phase 1/2 Active not recruiting 2 enrolled John Flickinger
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions with concurrent temozolomide for both schedules in patients with glioblastoma.

Timeline

Start
2021-12-14
Primary completion
2026-12
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Temozolomide Small molecule 75 mg/m2 Oral
Comparator Temozolomide Small molecule 150 mg/m2 Oral

Indications

glioblastoma